Bell Potter slaps buy rating on this profitable, dividend-paying ASX cannabis share

This cannabis share is smoking the market on Monday…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cronos Australia Ltd (ASX: CAU) share price was a strong performer on Monday.

The medicinal cannabis company's shares ended the day 15% higher at 55 cents.

At one stage, the Cronos Australia share price even reached a record high of 58 cents.

two men in formal business clothing closely inspect a bud from a cannabis crop.

Image source: Getty Images

Why did the Cronos Australia share price fire up?

Investors have been scrambling to buy the company's shares over the last two trading sessions thanks to a bullish broker note out of Bell Potter.

According to the note, the broker has initiated coverage on the company with a buy rating and 60 cents price target.

Based on the current Cronos Australia share price, this implies further potential upside of 9.1% for investors.

What did the broker say?

Bell Potter likes the company due to its leadership position in medicinal cannabis distribution. It explained:

Cronos Australia is a medicinal cannabis company that is the market leader in distribution to pharmacies and provides patient consulting services through its clinic business. The key driver for the impressive growth in the past 24 months has been the CanView platform which provides the widest range of medicinal cannabis products compared to competitors (Anspec, Health House).

The current system provides access to patients, doctors and pharmacists. The transition to CanView 2.0 streamlines the consultation and prescription process.

In addition, the broker highlights that Cronos Australia is a profitable, dividend-paying cannabis share. The only one of its kind in Australia. Furthermore, it feels its valuation is fair and its growth outlook is strong. The broker concludes:

We initiate coverage on Cronos with a Buy recommendation. We expect the momentum observed in FY22 to continue into FY23 and translate into strong revenue and earnings growth. Cronos is currently the only profitable dividend paying medicinal cannabis company on the ASX and the valuation does not appear demanding relative to the expected growth.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A smiling woman holds a Facebook like sign above her head.
Broker Notes

5 ASX shares scoring upgraded ratings this week

Experts have raised their ratings on JB Hi-Fi, Beach Energy, Amcor, and others this week.

Read more »

A man sitting at his dining table looks at his laptop and ponders the share price.
Broker Notes

Down 65%: Is this ASX 300 stock a cheap buy?

This stock has been sold off. Has this created a buying opportunity? Let's see what Bell Potter is saying.

Read more »

Three guys in shirts and ties give the thumbs down.
Broker Notes

5 ASX All Ords shares downgraded by brokers this week

Brokers have reduced their ratings on PLS Group, Fortescue, Webjet, and others this week.

Read more »

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Broker Notes

Does Ord Minnett rate Goodman shares as a buy, hold, or sell?

The broker has been looking at a big agreement signed this month.

Read more »

Red sell button on an Apple keyboard.
Broker Notes

Sell alert! Why this expert is calling time on Westpac shares

A leading analyst delivers his verdict on Westpac shares.

Read more »

A woman wearing a black and white striped t-shirt looks to the sky with her hand to her chin, contemplating buying ASX shares.
Broker Notes

Buy, hold, sell: Minerals 260, 4DMedical, Karoon Energy shares

Two experts share their latest ratings and opinions on three ASX shares.

Read more »

Two mining workers in orange high vis vests walk and talk at a mining site.
Resources Shares

Morgans tips 1 ASX mining share to rip — and 1 to avoid — in 2026

Morgans has revised its ratings on an ASX 200 lithium share and an ASX 200 gold stock.

Read more »

Woman and man calculating a dividend yield.
Broker Notes

What is Morgans saying about Stanmore Resources and Suncorp shares after results?

Are these shares a buy, hold, or sell?

Read more »